AIOM· @AIOMtweet · X·· 15 hours agoScore70
Body
#melanoma ad alto rischio: per la prima volta un #vaccino terapeutico dimostra la sua efficacia.
Se ne discute oggi ad #ESMO26, dove vengono presentati i dati di #INTerpath-001: https://www.medinews.it/comunicati/melanoma-nuova-combinazione-riduce-del-42-il-rischio-di-recidiva-per-la-prima-volta-il-vaccino-terapeutico-e-efficace-contro-il-cancro/
@myESMO
63 views · 1 like · 1 repost · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: AIOM · x.com